EBT Medical and NinaMED raise $13.75M to tackle overactive bladder
What's the deal? EBT Medical and NinaMED have announced $13.75M in financing to advance the NiNA System®, a licensed medical device designed to treat overactive bladder. The funding will support the development and commercialisation of the technology in the US market.
Why now? Overactive bladder affects millions of people and remains an underserved condition with limited treatment options beyond medication. The investment signals growing investor appetite for medtech solutions that address chronic conditions with large patient populations.
The signal: Both EBT Medical and NinaMED are classified as early growth-stage companies, suggesting this $13.75M raise is a meaningful inflection point as they move from clinical development toward US commercialisation. Wearable neuromodulation — NinaMED's core focus — sits at the intersection of two investor-friendly trends: non-invasive medtech and chronic disease management, positioning the partnership to capture a market where current pharmacological treatments often fall short on patient satisfaction.
Read more: prnewswire.com
